Discovery of Novel Flavonoid-Based CDK9 Degraders for Prostate Cancer Treatment via a PROTAC Strategy

Scientists presented findings that demonstrated the potential of CP-07 as a powerful flavonoid-based CDK9 degrader for prostate cancer therapy.